The results demonstrated that high DLX2 expression significantly reduced the survival rate of gastric cancer patients, with statistically significant differences observed in overall survival (OS), first progression (FP), and postprogression survival (PPS) (Figure 1A). This evidence concerns the gene DLX2 and gastric cancer.